Jun. 11 at 9:12 AM
$CYCN
Cyclerion CVR
(ii) with respect to Cyclerion’s right to receive payments under that License Agreement, dated June 3, 2021, between Cyclerion and Akebia Therapeutics, Inc. (the “Akebia License Agreement”), the earlier of (A) the fifteenth (15th) anniversary of the date of entry into the Cyclerion CVR Agreement and (B) the expiration pursuant to its terms or earlier termination by Akebia of the Akebia License Agreement, and
(iii) with respect to the sale, transfer or other disposition of the equity interests of Tisento Therapeutics Holdings, Inc. (“Tisento”) beneficially owned by Cyclerion, the earliest of (A) nine (9) months following the date of the consummation of Tisento’s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B) the sale of Tisento, and (C) the seventh (7th) anniversary of the Closing Date.
